Full text is available at the source.
Abstract
Changes in recorded background glucose-lowering active-substance counts were evaluated after initiating a GLP-1 or dual GIP/GLP-1 receptor agonist.
- The evaluation focused on the impact of GLP-1 or dual GIP/GLP-1 receptor agonists on glucose-lowering medications.
- Changes in medication counts may indicate shifts in treatment strategies following the initiation of these agonists.
- The findings are preliminary and require further investigation to determine their significance.
Simplified